Early testing for AADC deficiency in newborns in Liguria
This study tests newborn babies in Liguria, Italy for AADC deficiency, a rare genetic condition that affects the brain and movement. Early detection may allow earlier treatment and better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby is born at one of the participating birth centers in the Liguria region of Italy.
- You or your legal caregiver must give written permission before your baby can join.
- The study only includes newborns, so enrollment happens shortly after birth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early brain signals that may predict future language difficulties in very young children. It compares babies with a family history of language problems to babies without, using safe testing to see what markers show up early.
This early-stage trial tests VGN-R09b, a gene therapy, given to children with AADC deficiency who are not doing well on standard medicines. It aims to improve symptoms and quality of life by addressing the underlying cause of AADC deficiency.
This Phase 1 trial tests how safe different treatment doses are for children with AADC deficiency, using MRI-guided brain surgery. It may help improve movement and developmental progress after standard medicines did not work well enough.
This study looks at brain scans and other tests in babies and young children with ataxia telangiectasia (A-T), a rare genetic condition that affects movement and coordination. The goal is to find early signs of the condition to help plan future treatments.
This study aims to better understand different developmental and psychological conditions in children by looking at their symptoms and behaviors, and may help improve future diagnosis and care.
This study looks at immune cells in blood to better understand rare brain conditions caused by genetic changes. It may help researchers understand why symptoms happen and how the immune system is involved.
Hear when a new Neurology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.